Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PF-08634404 + Chemotherapy vs Bevacizumab + Chemotherapy in Metastatic Colorectal Cancer
NCT07222800Phase 3Recruiting
- Sponsor
- Pfizer
- Start
- Dec 2025
- Primary completion
- Feb 2030
- Modality
- Bispecific Antibodies
- Countries
- 17
01
Overview
Phase 3, randomised, double-blind trial of PF-08634404 in colorectal cancer (CRC) (2 arms), sponsored by Pfizer. Primary endpoints: Progression-Free Survival per RECIST 1.1 by BICR at 4 years and Overall Survival at 4 years. Started Dec 2025; status: recruiting.
02
Drugs
PF-08634404
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT07222800.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07222800.